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Simple Summary: In this review, we discuss treatment strategies in biliary tract cancers (gallbladder
cancer, intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma). In particular, we will
describe advances in cellular therapies and cancer vaccines for biliary tract cancers, followed by our
local experience with combining a melanoma-associated antigen (MAGE)-positive cell lysate-based
autologous dendritic cell vaccine and anti-angiogenic therapy (bevacizumab) in a case of stage IV
gallbladder cancer.
Abstract: Biliary tract cancer (BTC) is a rare, but aggressive, disease that comprises of
gallbladder carcinoma, intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma,
with heterogeneous molecular profiles. Advanced disease has limited therapeutic options beyond
first-line platinum-based chemotherapy. Immunotherapy has emerged as a viable option for many
cancers with a similar unmet need. Therefore, we reviewed current understanding of the tumor
immune microenvironment and recent advances in cellular immunotherapy and therapeutic cancer
vaccines against BTC. We illustrated the efficacy of dendritic cell vaccination in one patient with
advanced, chemorefractory, melanoma-associated antigen (MAGE)-positive gallbladder carcinoma,
who was given multiple injections of an allogenic MAGE antigen-positive melanoma cell lysate
(MCL)-based autologous dendritic cell vaccine combined with sequential anti-angiogenic therapy.
This resulted in good radiological and tumor marker response and an overall survival of 3 years
from diagnosis. We postulate the potential synergism of adding anti-angiogenic therapy, such as
bevacizumab, to immunotherapy in BTC, as a rational scientific principle to positively modulate the
tumor microenvironment to augment antitumor immunity.
Keywords: biliary tract cancer; review; immunotherapy; cell therapy; personalized medicine;
dendritic cell vaccine; bevacizumab
1. Introduction
Biliary tract cancer (BTC) is a rare but clinically aggressive cancer that accounts for 3–5% of
cancer diagnoses globally. It is a heterogeneous disease comprising gallbladder carcinoma (GBC),
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intrahepatic cholangiocarcinoma (IHCC) and extrahepatic cholangiocarcinoma (EHCC). With an
increased understanding of the differing anatomical, histological and molecular subtypes of biliary
tract cancers, novel therapies have emerged in the last two decades. However, chemotherapy remains
the standard of care in first-line metastatic biliary tract cancers with modest efficacy. As such,
more research efforts are required in the subsequent lines of treatment for patients with advanced
stage disease.
2. Current Treatment Strategies in Advanced BTC
There is still a paucity of highly efficacious chemotherapy to treat advanced BTC. Following the
landmark phase III trial ABC-02, combination gemcitabine and cisplatin found first-line indication in
the treatment of advanced BTC, but with a median overall survival (OS) of only slightly under a year [1].
More recently, a Japanese phase III trial comparing gemcitabine-Tegafur/Gimeracil/Oteracil (TS-1®)
with the established gemcitabine-cisplatin regimen proved non-inferiority of the aforementioned
regimen [2]. Other internationally acceptable regimens include gemcitabine-oxaliplatin and
gemcitabine-capecitabine, both supported by phase II data. Subsequently, dose intensification of
gemcitabine-cisplatin with the addition of TS-1 [3] or nab-paclitaxel [4] has been attempted. While these
increased the response rates and overall survival by a small margin, they also resulted in higher
toxicities. Second-line options include fluoropyrimidine-based chemotherapy (e.g., FOLFOX) [5] in
combination with oxaliplatin or irinotecan, but overall survival results remain disappointing.
The advent of molecular testing and next-generation sequencing (NGS) have unveiled potential
treatment options for chemo-refractory disease. Biliary tract cancers have multiple molecular
alterations and significant intra-tumoral heterogeneity, with variations of molecular profile across
IHCC, EHCC and GBC. Main oncogenic mutation pathways include that of Wnt-Catenin Beta 1
(WNT-CTNNB1), MYC, ErbB, tumor necrosis factor (TNF) and vascular endothelial growth factor
(VEGF) signaling, and this is part of a complex genomic network that modulates cell cycle regulation,
DNA damage, MYC amplification, epigenetic regulation, demethylation, kinase signaling and immune
dysregulation [6]. In the MOSCATO trial, 68% of patients with biliary tract cancer (n = 43) were
identified to have potentially actionable mutations, 33% of which had an objective response [7].
Recently, a few targetable mutations have emerged as well.
The fibroblast growth factor (FGF) pathway upregulates the mitogen-activated protein kinase
(MAPK) and phosphatidylinositol 3-kinase-A (PI3KA) pathways; FGF receptor 2 (FGFR2) gene
alterations are particularly involved in the pathogenesis of cholangiocarcinoma (CCA) and harbored
by about 9–16% of patients. In the FIGHT-202 trial [8], pemigatinib (selective, oral inhibitor of FGFR1,
2 and 3) was found to achieve high response rates (36%, including three complete responses) and
disease control rates (80%) in patients with FGFR2 fusions or rearrangements as compared to those
who had no FGF/FGFR alterations, with a duration of disease control of about 7.5 months. This led
to an accelerated US Food and Drug Administration (FDA) approval. A phase III trial comparing
pemigatinib to gemcitabine-cisplatin in the first-line setting for patients with advanced BTC with
FGFR2 alterations is also underway.
Isocitrate dehydrogenase 1 (IDH1) is a key enzyme involved in the citric acid cycle, and mutations
in this enzyme have been linked to oncogenesis. IDH1 mutations are present in 25% and IDH2
mutations in 3% of BTC patients, particularly in intrahepatic cholangiocarcinoma [9]. ClarIDHy is a
phase III trial that explored Ivosidenib (small molecule inhibitor of IDH1) in patients with IDH-mutated
BTC, and showed improved progression-free survival (PFS) and overall survival even in pre-treated
patient populations [10].
Neurotrophic tyrosine receptor kinase (NTRK) rearrangements are rare in incidence in BTC (<5%),
but could still be a potential drug target. Larotrectinib or Entrectinib are approved for patients with
such rearrangements in view of durable response rates of up to 75% in a phase II study [11]. There has
also been promising antitumor activity demonstrated in BRAF-mutated and epidermal growth factor
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receptor (EGFR)-mutated BTC patients, such as the use of Dabrafenib and Trametinib [12], as well as
Erlotinib alone or in combination with Bevacizumab [13].
BTCs usually do not have high mutational burden; in a report of 239 BTC tumors, where whole
exome sequencing (WES) was performed, the median numbers of mutations across the IHCC, EHCC and
gallbladder cancer subtypes were 39, 35 and 64, respectively, with only 5 patients showing a deficient
mismatch repair (dMMR) or microsatellite instability-high (MSI-H) genotype [14]. The MSI-H or dMMR
status confers a higher neoantigen load and tumor mutational burden (TMB), leading to a potential
increase in responsiveness to immune checkpoint inhibitors. The KEYNOTE 158 study highlighted
how MSI-H BTC patients had response rates as high as 40% with duration of responses more than
2 years, and that patients with high TMB also correlated with greater benefit from immunotherapy [15].
Even for patients with microsatellite-stable (MSS) BTC, other biomarkers like programmed death
ligand 1 (PD-L1) overexpression also predict for better response from immunotherapy, as evidenced by
a phase II trial demonstrating partial response in patients with MSS BTC treated with nivolumab in the
second-line setting [16].
Emerging data suggest that in a biomarker unselected population, there can also be
durable responses to combination immunotherapy such as Nivolumab and Ipilimumab [17].
Gemcitabine-cisplatin was combined with durvalumab alone or in addition to Tremelimumab in
advanced BTC, and showed promising efficacy and tolerability with response rates at 70% and disease
control rates (DCR) in 90% of patients with good response durability [18]; this is currently being further
evaluated in the phase III TOPAZ-1 trial. In addition, gemcitabine-cisplatin was also combined with
nivolumab in another phase II trial [19] and similarly showed clinical efficacy with comparable DCR
and manageable toxicities.
3. Inflammation and BTC
The causative link between inflammation and biliary tract cancer has been well established in
various types of BTC—the association of gallbladder carcinoma with cholelithiasis-induced chronic
inflammation, EHCC with parasites (e.g., liver fluke infections) and chronic pancreatitis and IHCC
with persistent hepatolithiasis and hepatitis viruses [20–22]. Primary biliary sclerosis and primary
sclerosing cholangitis are autoimmune conditions that also lead to inflammation and increased risk for
BTC development [23].
One study suggested that chronic inflammation may lead to biliary tract cancers through
aberrant activation-induced cytidine deaminase (AID) expression, resulting in the generation
of somatic mutations in key cancer genes including TP53, c-MYC and promotor region of
INK4A/p16. Inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), transforming
growth factor-beta (TGF-β), interleukin-6 (IL-6) and other cytokines/chemokines have been known
to enhance tumor proliferation, activate epithelial-to-mesenchymal transition (EMT) and promote
metastatic potential [24–26]. In particular, sustained IL-6-STAT3 signaling was shown to contribute
to tumorigenesis and cholangiocyte transformation during chronic inflammation or fibrosis via the
alteration of EGFR promotor methylation and inhibition of apoptosis [27]. Furthermore, some small
studies have shown correlation between IL-6 and overall survival outcomes—patients who had a
higher level of IL-6 levels tended to have a higher systemic burden and also worse overall survival [28].
More studies are required to evaluate the role of IL-6 as not only a potential target, but also a biomarker
in BTC.
Notably, cholangiocarcinomas are often found to harbor both inflammatory cells (T cells, B cells,
natural killer cells, neutrophils and macrophages) and a high amount of tumor stroma, including
vasculature, extracellular matrix (ECM) and fibroblasts including cancer-associated fibroblasts (CAFs)
and mesenchymal stromal cells (MSCs) [29,30]. Key growth factors such as platelet-derived growth
factor (PDGF-DD), FGF and TGF-β also aid CAF infiltration and other mediators (some in the form
of exosomes) influence crosstalk with CCAs [31]. One report analyzed the TME in over 500 IHCC
and found that while 45% were immune-desert (“cold” phenotype), more than 50% of CCAs were
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immune-infiltrated with 11% showing very high immune cell infiltration (“hot” phenotype) [32]. It was
also shown that the tumor stroma in CCA is composed of α-smooth muscle actin (α-SMA)-positive
CAFs that outweigh the tumor itself and form a barrier against the infiltration of immune cells [30,33].
Furthermore, transcriptomic results from 10 IHCC tumors found high vascular endothelial growth
factor (VEGF) expression, which is thought to induce remodeling of the tumor microenvironment
(TME) and limit T-cell infiltration, therefore leading to lower responsiveness to immunotherapy [34].
Immunosuppressive mediators such as indoleamine 2,3-dioxygenase (IDO), interleukin-10 (IL-10) and
TGF-β are also highly expressed in CCAs; these mediators can suppress the function of effector, cytotoxic
T lymphocytes (CTL) and increase the migration of innate immune cells such as tumor-associated
neutrophils (TANs), tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells
(MDSCs) into the tumor [35].
Apart from an immunosuppressive TME, studies also revealed immune escape mechanisms of
certain BTCs in the form of major histocompatibility complex-I (MHC-I) downregulation, which was
associated with poorer prognosis in BTC and lower tumor-infiltrating lymphocyte (TIL) infiltration [36].
In the same report, TIL infiltration was noted in about half of the 375 resected BTC tumors and it
correlated positively with overall survival. Other studies also showed the abundance of CD8+ T
cells within the tumor, while more CD4+ T cells were found in the tumor–liver interface [37], and an
association between longer overall survival and the presence of tumor-infiltrating CD4+ or CD8+ T
cells [38–40].
4. Cellular Immunotherapy and Cancer Vaccine in BTC
Though immune checkpoint inhibitors have therapeutically revolutionized the field of oncology,
their efficacy in advanced BTC is still under active investigation. In view of the limited effective
treatment options, there has been increased research in personalized cell-based therapy and cancer
vaccines, either as a stand-alone treatment or in combination with other systemic therapies. Among cell
therapy approaches, adoptive T-cell therapy, peptide-derived vaccines and dendritic cell (DC) vaccines
have emerged with positive clinical outcomes in case reports and early phase clinical trials.
Adoptive T-cell therapy refers to the process where patients’ T lymphocytes are extracted and
isolated from tumor or blood. They are then activated and expanded in vitro, some with genetic
modification, then re-infused usually following lymphodepletion chemotherapy. Such therapies can
exist in the form of autologous TIL infusion, chimeric antigen receptor T-cell (CAR-T) therapy targeting
specific surface tumor antigens and genetically-modified (GM) T-cell receptor (TCR) T-cell therapy.
A case report in 2006 first suggested the clinical efficacy of adoptive cell therapy in BTC. A patient
with IHCC with lymph node involvement received radical resection and was treated with adjuvant
CD3-activated T cells plus tumor lysate- or peptide-pulsed dendritic cells and survived over 3.5 years
following treatment [41]. Subsequently, Rosenberg’s team in National Institute of Health (NIH)
reported in 2014, a case of a metastatic cholangiocarcinoma patient, who received TIL infusion that
had been co-cultured with antigen-presenting cells (APCs) transfected with somatic non-synonymous
mutations identified in the tumor, resulted in tumor regression for 7 months [42]. An adjuvant trial
then reported 36 BTC patients post-resection, who received activated T-cell transfer and vaccinated
with autologous tumor lysate-pulsed DCs. The median PFS was improved at 18.3 months in patients
who received adjuvant immunotherapy compared with 7.7 months in those with surgery alone
(p = 0.005). Overall survival reached 31.9 months in patients receiving adjuvant immunotherapy
compared with 17.4 months (p = 0.022) in patients who did not receive it [43]. A recent phase I study
of 11 human epidermal growth factor receptor 2 (HER2)-positive advanced BTC (n = 9) and pancreatic
adenocarcinoma (n = 2) patients treated with HER2-targeted CAR-T therapy demonstrated disease
control in 4/9 BTC patients, which included a partial response (PR) that lasted 4.5 months. The infusion
of CAR-T-HER2 cells was safe without significant adverse events, except for one grade 3 (G3) febrile
event and another G3 transaminitis [44].
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As immunogenic targets, tumor-associated antigens (TAAs) such as Wilms’ tumor protein 1 (WT1)
and mucin protein 1 (MUC1) emerged as potential peptide vaccine options in BTC. WT1 mutations
were found in about 80% of BTC, while MUC1 was reported to be overexpressed in 90% of BTC.
Both are associated with worse prognosis across various cancers [45]. A dose-escalation phase I study
of WT1 peptide vaccination in combination with gemcitabine in 8 patients with advanced BTC reported
stable disease at 2 months in 4/8 patients and a median OS of 288 days. WT1-specific T cells were
detectable in 5/8 of patients after vaccination [46]. Another phase I trial of MUC1 peptide vaccine was
conducted in 8 patients with advanced pancreatic and biliary cancers with good safety profile, though
disease progression was noted in 7/8 patients [47].
Subsequently, Human Leukocyte Antigen (HLA)-matched multiple peptide vaccinations
were attempted to increase specific antitumor responses. In one case report, whole exome
sequencing, whole transcriptomic sequencing and HLA ligandome analyses were used to identify the
immunopeptidome that led to the creation of a personalized multi-peptide vaccine (7 non-mutated
tumor-associated peptides) emulsified in adjuvant Montanide. This vaccine was administered
as multiple dosing to a 56-year-old patient with advanced IHCC, who had also undergone several
surgeries for removal of the primary tumor, locoregional recurrences and lung metastasis. She remained
recurrence-free for over 41 months [48]. A phase I trial reported a quadruple peptide vaccine therapy
(HLA-A*2402-restricted epitope peptides) in 9 patients with advanced and chemorefractory BTC [49].
Peptide-specific T-cell immune responses were observed in 7/9 patients and clinical responses were
observed in 6/9 patients. The median PFS and OS were 156 and 380 days, respectively. In a subsequent
phase I trial by the same authors, a 3-peptide combination vaccine that includes cycle association
protein 1 (CDC1), cadherin 3 (CDH3) and kinesin family member 20A (KIF20A) was administered to 9
patients with advanced BTC [50]. Again, this was well tolerated and resulted in peptide-specific T-cell
responses in all patients, with stable disease seen in 5/9 patients. A separate phase II multi-peptide
vaccine trial was reported, with the difference of each vaccine being personalized, selecting up to four
HLA-matched peptides. This vaccine induced T-cell responses in 8/17 patients who completed the
first cycle of vaccination and 4/7 patients following the second cycle [51]. Personalized multi-peptide
vaccination remains labor-intensive, but appears to have better tumor control in selected BTC patients.
Interestingly, a phase II trial reported the combined use of Gemcitabine with Elpamotide,
an HLA-A*24:02-restricted epitope peptide of VEGF receptor (VEGFR)-2. The reported response rate
was 18.5%, with median survival of 10.1 months, which was longer than that of the historical control,
and the 1-year survival rate was 44.4%. Injection site reactions were observed in 64.8% of these patients,
suggesting the presence of delayed hypersensitivity caused by sensitization of peptide-reactive T cells.
In these patients, median OS was significantly longer (14.8 months) compared to those with no injection
site reactions (5.7 months) [52].
Dendritic cells are potent professional APCs and effective therapeutic cancer vaccine vehicles that
present tumor antigens. The only therapeutic cancer vaccine that has been approved by the FDA is
Sipuleucel-T, an autologous active cellular immunotherapy that consists of activated monocytes as
APCs presenting a recombinant fusion protein of prostatic acid phosphatase fused to immunostimulant
granulocyte-macrophage colony-stimulating factor (GM-CSF) against metastatic castrate-resistant
prostate cancer, demonstrating improvement in overall survival [53]. In one retrospective study,
WT1 and MUC1-pulsed DC vaccination was given to 65 patients with unresectable or recurrent BTC
with good tolerability. The objective clinical response remained modest with partial response in only
6% of patients, stable disease in 23% of patients and median survival of 7.2 months from the time of
vaccination [54]. Another phase I/II study also used MUC1-loaded DC vaccine as adjuvant therapy in
12 patients with resected BTC and pancreatic cancer. Despite the detection of increased CD8+ and
CD4+ T-cell responses, vaccination did not induce anti-MUC1 antibody responses. Median OS was
26 months with 33% of patients without disease recurrence after 4 years [55]. These results again show
the potential efficacy of tumor-associated antigen (specifically WT1 and MUC1)-loaded DC vaccines in
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disease control and it remains an active area of investigation. Tumor lysate-based DC vaccines in BTC
remain as investigational therapies, though early efficacy was seen in in-vitro studies [56].
Strategies to improve the clinical efficacy of a therapeutic cancer vaccine or adoptive T-cell therapy
in BTC include discovery of personalized neoantigens to tailor greater personalized immunotherapy.
Preclinical organoid or cell line models may be able to reveal key mutations and mediators that
influence TIL infiltration or response to immunotherapy, and can potentially aid in future cell therapy
development [57]. Separately, deep integrative genomic analysis can uncover significant and potentially
immunogenic genetic mutations. For example, a recent large study on GBC uncovered significantly
mutated genes related to ERBB2, ERBB3, KRAS, PIK3CA and BRAF, and neoantigens from several
mutated GBC genes including ELF3, ERBB2 and TP53 that were proven to activate T cells, therefore
being potential candidate antigens for a therapeutic cancer vaccine. In particular, frame shift mutations
in ELF3 led to the identification of several immunogenic cancer neoantigens [58].
Carcinogenesis in BTC arises through a complex interaction between extracellular ligands and
intracellular signaling pathways—an amalgamation of pro-inflammatory cytokines and growth factors
as well as aberrant activation and deregulation that orchestrate disinhibited cell proliferation and
genetic/epigenetic alterations. It is therefore important to further understand and hence better modulate
the tumor immune microenvironment of the BTC to overcome the resistance mechanisms toward cell
therapy. Overcoming the immunosuppressive TME through combination approaches such as with
immune checkpoint inhibitors, targeted therapy and chemotherapy may potentially improve future
treatment outcomes of cell therapy.
5. A Case of Refractory GBC that Achieved Clinical Benefit with DC Vaccination in Combination
with Anti-Angiogenic Therapies
Our institution, National Cancer Centre Singapore (NCCS), had previously reported a phase II
clinical trial of an allogeneic melanoma cell lysate (MCL)-based autologous DC vaccine in 20 metastatic
colorectal cancer patients, whose tumors were biopsy-proven for expression of melanoma-associated
antigen (MAGE)-A [59]. This DC vaccine subsequently obtained NCCS’ Institutional Ethics Committee
approval as part of a non-profit, named-patient compassionate use program for gastrointestinal cancer
patients who progressed after conventional systemic treatments and were no longer recommended for
any further standard therapies. Of the 78 real-world patients who were treated on the MCL-based DC
vaccine compassionate use program, 7 received DC vaccine and bevacizumab (DC+Bev) combination
and the most recently treated patient had advanced gallbladder cancer with confirmed MAGE-A
expression. To date in 2020, this case remains as the only gallbladder cancer treated with the DC+Bev
compassionate use program.
Our patient presented in December 2013 with recurrent MSS gallbladder cancer with liver, lung and
peritoneal metastases. He was 83 years old, had poor performance status (ECOG 2) and had received
multiple lines of prior systemic chemotherapy with radiologically proven progression of disease before
he was referred to NCCS. He started treatment with DC+Bev in December 2014 and achieved a dramatic
reduction in Carbohydrate Antigen (CA) 19-9 and neutrophil-to-lymphocyte (NLR) ratio (Figure 1) after
three cycles of treatment. Repeat positron emission tomography-computed tomography (PET-CT) scan
in January 2015 showed significant PR with resolution of the 2.3 cm liver metastasis and near resolution
of the lung metastasis (Figure 2). After an episode of enterocutaneous fistulation and gallbladder
abscess, bevacizumab was discontinued and DC vaccination was resumed with oral thalidomide,
which also has anti-angiogenic properties, but no known risks of fistulation. On this combination,
his CA 19-9 levels declined and he remained with stable disease until the 15th cycle of DC vaccine.
Following this, the patient received anti-programmed death 1 (PD1) immunotherapy (nivolumab) at
a private oncology clinic with rapid disease progression. He was then re-challenged with a second
course of DC + thalidomide combination. Significant clinical response was observed again, with CA
19-9 levels reducing by more than 80% from over 10,000 U/mL to 1251 U/mL. PET-CT scan in February
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2016 again revealed PR in the gallbladder mass and peritoneal nodules. Eventually, he progressed on
treatment and subsequently passed away in December 2016 after stopping all treatments in November.Cancers 2020, 12, x 7 of 15 
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Figure 2. Resolution of liver and lung metastasis in the patient after commencing dendritic cell (DC)
vaccine and bevacizumab. (A) Positron emission tomography-computed tomography (PET-CT) done
prior to any treatment in week 3 showing 0.5 cm lung metastasis. (B) PET-CT done in week 13 showing a
reduction in size of lung metastasis that became unmeasurable. (C) PET-CT done prior to any treatment
in week 3 showing a 2.3 cm liver metastasis. (D) PET-CT done in week 13 showing resolution of the
liver metastasis.
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than baseline reference ranges for healthy individuals, they were found to decrease during periods
of treatment response compared to pre-treatment and disease progression time points (Figure 3).
Peripheral blood immune cell profiling by flow cytometry analysis showed that the frequency of
monocytic myeloid-derived suppressor cell (MDSC, CD14+HLADR−) population corresponded with
cancer progression and treatment—lower during periods of treatment response and higher during
pre-treatment and disease progression. The overall CD4 and CD8 T-terminal effector (TEMRA) cells,
on the other hand, decreased as the disease progressed (Figure 4).
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the first cycle of DC vaccine + anti-angiogenic combination (week 42 and during disease progression
(week 89).
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Figure 4. Plasma cytokine profile of Patient 7. Using the Luminex assay, it was observed that, while the
plasma cytokine levels of interleukin (IL)-1a, IL-1b, IL-2, IL-6, IL-10, VEGF and fibroblast growt factor
2 (FGF2) were all higher than baseline reference ranges for healthy individuals pre-treatment [10];
they were found to be lowered during periods of treatment response compared to pre-treatment and
disease progression time points.
7. Discussions
Our patient had a good response during 2 years of combined DC vaccine and anti-angiogenic
therapy, and survived 3 years from diagnosis of stage IV GBC with a good quality of life. It is noteworthy
that this patient had previously received multiple systemic therapies including bevacizumab prior to
consulting us at NCCS. We are encouraged by this finding and would like to postulate the potential
synergism between anti-angiogenic therapy and the DC vaccine in selected patients, though this needs
to be confirmed through larger clinical trials.
The addition of the anti-VEGF-A antibody, bevacizumab, to the DC vaccine therapy aims
to harness a potential synergistic effect. The mode of action for bevacizumab has been described,
including anti-angiogenesis, remodeling the immunosuppressive TME to favor effector T-cell trafficking,
infiltration and optimal killing [60,61]. However, its single agent activity across cancers remains minimal,
being most useful as part of a chemotherapy backbone or together with other biologic agents [62].
Given its pivotal role of normalizing tumor vasculature and reprogramming the tumor immune
microenvironment, there is rationale for combining cancer immunotherapy with anti-angiogenic
therapy to improve the treatment outcome. Anti-VEGF therapy had also been successfully combined
with DC vaccine therapy in the co text f advanced glioblastoma [63] and ovari n cancers [64],
both wit positive safety and clinical signals. e t at combination anti-angiogenic therapy
may have a st l in improving cell-based therapy in advanced BTC, giv n the high amount
of hypoxia/desmoplasia, VEGF expression and stromal CAFs in the tumor microenvironment of
these cancers.
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We had previous clinical experience of using thalidomide combinations in advanced
gastro-esophageal adenocarcinoma [65] and hepatocellular carcinoma [66]. Thalidomide is
well documented to possess both anti-angiogenic and immunomodulatory properties [67,68].
The aforementioned case is the first clinical evidence combining DC vaccination and thalidomide
in any solid tumor to our knowledge. Previously, there were only a few clinical reports of the use
of the thalidomide analog lenalidomide as an immune adjuvant to DC vaccines in hematological
malignancies [69,70]. In vivo findings from these studies confirmed lenalidomide’s immunomodulatory
effects; vaccine-specific immune responses and critical maintenance of T-cell persistence in vivo were
higher with its concomitant administration. Pre-clinical data demonstrated both antitumor cytotoxic
effects as well as its effect as a vaccine immune modulator.
8. Conclusions
There remains an unmet need for BTC patients who are chemo-refractory or do not harbor specific
targetable mutations. Encouraging clinical signals are seen in earlier clinical trials of therapeutic
cancer vaccination and adoptive T-cell therapy in these patients, indicating a potential, emerging role
for cellular immunotherapy against BTC. We believe that our real-world case of an elderly patient
with heavily pre-treated GBC who responded to DC vaccination in combination with sequential
anti-angiogenic drugs is an example of the nascent yet possible role of cancer vaccines in BTC. It also
illustrates the importance of choosing rational combinations to overcome the immunosuppressive
tumor microenvironment and augment an antitumor immune effect. The increasing utilization of
personalized, tumor-specific antigens with next-generation sequencing and neoantigen predictive
platforms harnessed as targets for immunotherapy is also highly anticipated.
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